Misoprostol reduces indomethacin-induced changes in human small intestinal permeability

Digestive Diseases and Sciences
I BjarnasonA J Levi

Abstract

This study examined whether indomethacin-induced increases in small intestinal permeability in man are prevented by concomitant administration of a prostaglandin analog (misoprostol). Twelve male volunteers were tested as baseline, following misoprostol alone (200 micrograms, at -16, -12, -8.5, -4, -1.5, and +4 hr); following indomethacin alone (75 mg, at -8; 50 mg, -1 hr); and following coadministration of misoprostol and indomethacin as specified above. A 100-ml test solution containing 3-O-methyl glucose (0.2 g), D-xylose (0.5 g), L-rhamnose (1.0 g), and [51Cr]EDTA (100 microCi) was ingested at 8 AM, and a 5-hr collection made for marker analysis to assess active and passive carrier-mediated transport and trans- and intercellular permeation, respectively. Indomethacin increased the permeation of [51Cr]EDTA selectively, and this increase was significantly reduced by the coadministration of misoprostol. These changes were mirrored by changes in [51Cr]EDTA-L-rhamnose urine excretion ratios, which indicates that paracellular permeability was specifically altered. This study supports the suggestion that NSAIDs alter intestinal permeability by a mechanism involving reduced prostaglandin synthesis and indicates that coadministratio...Continue Reading

References

May 1, 1986·British Journal of Rheumatology·A W SegalM L Snaith
Jun 26, 1987·Deutsche medizinische Wochenschrift·I O AuerC Eilles
Jul 1, 1988·Gastroenterology·R M Craig, A J Atkinson
Sep 1, 1987·Gut·I Bjarnason, J Peters
Jan 1, 1987·Scandinavian Journal of Rheumatology. Supplement·I BjarnasonA J Levi
Jan 1, 1986·Digestive Diseases·I BjarnasonA J Levi
Jul 1, 1985·Digestive Diseases and Sciences·M M CohenJ D'Souza
Oct 1, 1983·Digestive Diseases and Sciences·J N HuntL Kessler

❮ Previous
Next ❯

Citations

Sep 1, 1995·Journal of Cellular Physiology·T Y MaD Bhalla
Mar 1, 1993·Digestive Diseases and Sciences·G R DaviesD S Rampton
Mar 1, 1996·Digestive Diseases and Sciences·X HebuterneP Rampal
Sep 1, 1995·Journal of Pharmacological and Toxicological Methods·J FordJ B Houston
Jun 27, 2000·Prostaglandins & Other Lipid Mediators·B Mohajer, T Y Ma
Jan 5, 2002·Gastroenterology Clinics of North America·C W Houchen
Jan 13, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David Y GrahamWaqar A Qureshi
Aug 5, 1998·Alimentary Pharmacology & Therapeutics·N M Davies
May 8, 1999·Alimentary Pharmacology & Therapeutics·E D HondP Rutgeerts
May 1, 1991·Annals of the Rheumatic Diseases·S O'Mahony, A Ferguson
Sep 1, 1992·Annals of the Rheumatic Diseases·A B BallingerD L Scott
Apr 1, 1996·Annals of the Rheumatic Diseases·T MahmudI Bjarnason
Jan 1, 1994·Gut·I Bjarnason
Nov 21, 1998·Gut·G SigthorssonI Bjarnason
Feb 24, 2001·Pharmacotherapy·N M DaviesF Jamali
Mar 5, 2011·Journal of Clinical Biochemistry and Nutrition·Hirofumi MatsuiIchinosuke Hyodo
Apr 10, 2013·World Journal of Gastroenterology : WJG·John L Wallace
Feb 18, 2014·Current Gastroenterology Reports·Stephanie D Syer, John L Wallace
Feb 20, 2009·Journal of Gastroenterology·Ingvar Bjarnason, Ken Takeuchi
Feb 20, 2009·Journal of Gastroenterology·Laurence Maiden
Mar 26, 2009·Journal of Gastroenterology·Yoko Watanabe-FukudaKenji Watanabe
Jul 2, 2009·Journal of Gastroenterology·Kazuhide HiguchiTetsuo Arakawa
Aug 10, 2012·Journal of Gastroenterology·Massimo MontaltoRaffaele Landolfi
Aug 1, 1990·The American Journal of the Medical Sciences·M Feldman
Oct 19, 2010·Gastroenterology Clinics of North America·Carmelo Scarpignato, Richard H Hunt
Aug 22, 2006·Alimentary Pharmacology & Therapeutics·L LaineR W Dubois
Oct 7, 2004·European Journal of Pharmacology·Brendan J R Whittle
Feb 1, 1996·Baillière's Clinical Rheumatology·I Bjarnason, T J Peters
May 1, 1995·Gastroenterology·I BjarnasonD Hollander
Oct 25, 2002·The Journal of Pharmacy and Pharmacology·Igor Legen, Albin Kristl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.